ArticlePloS one2025
Longitudinal changes in each retinal layer thickness in patients with moderate or more severe diabetic retinopathy taking calcium dobesilate.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07232225 (OCT-Based Screening for Early Retinal Changes in Asymptomatic Diabetic Patients), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
OCT-Based Screening for Early Retinal Changes in Asymptomatic Diabetic Patients
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo longitudinally analyze the impact of calcium dobesilate (CaD) treatment on retinal layer thicknesses in patients with moderate or more severe diabetic retinopathy (DR).
methodsIn this retrospective, longitudinal study, patients with DR exhibiting moderate non-proliferative diabetic retinopathy (NPDR) or more advanced stages were enrolled and divided into two groups: those prescribed CaD for more than 6 months (Group 1) and those not prescribed CaD (Group 2). After the baseline visits, three additional examinations were conducted at 1-year intervals.
resultsIn total, 128 eyes were included: 38 in Group 1 and 90 in Group 2. Over time, group 2 exhibited significant decreases in ganglion cell complex (GCC) and inner nuclear layer (INL) thicknesses (P < 0.001 and P = 0.002, respectively), while Group 1 did not. Both groups experienced significant reductions in outer nuclear layer (ONL) thickness (P = 0.030 for Group 1 and P < 0.001 for Group 2). Group 2 exhibited a significantly greater decrease in GCC thickness compared with Group 1(P = 0.026).
conclusionsIn patients with moderate or more severe DR, the group taking CaD did not show significant reductions in GCC and INL thicknesses over time compared with the group not taking CaD. These findings suggest that CaD could have a protective effect on the inner retina, even in those with more advanced stages than mild DR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.